Drug class profile · refreshed daily from federal data

Thiazide Diuretic

30 molecules in this class, $122.0M combined CY2024 Part D spend across 27.6M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Thiazide Diuretic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 30tracked in Part D
CY24 Part D spend: $122.0Mcombined across class
Total Rx claims: 27.6M9.2M unique beneficiaries
Generic mfrs (active): 103across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Hydrochlorothiazide

Brand: INZIRQO · 27.6M Part D claims (CY24) · 9.2M beneficiaries · First FDA approval: 1973-01-12

11 generic mfrs 2 plans require PA Active FDA shortage

Low NADAC$0.012

→

Avg plan cost$0.089

Part D spend $122.0M 8× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

02

Chlorothiazide

Brand: Chlorothiazide · 367 Part D claims (CY24) · 147 beneficiaries · First FDA approval: 1962-02-15

5 generic mfrs 0 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $31649

Class share

0%

of class CY24 spend

View profile →

03

Amiloride and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 1989-12-01

2 generic mfrs 0 plans require PA

Low NADAC$0.450

→

Avg plan cost$0.450

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

04

Amlodipine Besylate Valsartan Hydrochlorothiazide

Brand: AMLODIPINE, VALSARTAN, HYDROCHLOROTHIAZIDE · — Part D claims (CY24) · First FDA approval: 2015-06-01

Brand-only (no generics) 0 plans require PA

Low NADAC$4.24

→

Avg plan cost$5.12

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

05

Amlodipine Valsartan and Hydrochlorothiazide

Brand: Exforge HCT · — Part D claims (CY24) · First FDA approval: 2009-04-04

Brand-only (no generics) 0 plans require PA

Low NADAC$15.45

→

Avg plan cost$15.45

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

06

Amlodipine,Valsartan and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2025-01-06

Brand-only (no generics)

Low NADAC$4.24

→

Avg plan cost$5.12

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

07

Benazepril and Hydrochlorothiazide

Brand: Lotensin HCT · — Part D claims (CY24) · First FDA approval: 1992-05-30

3 generic mfrs 0 plans require PA

Low NADAC$0.222

→

Avg plan cost$0.283

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

08

Bisoprolol and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2010-10-12

8 generic mfrs 0 plans require PA

Low NADAC$0.209

→

Avg plan cost$0.214

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

09

Candesartan Cilexetil and Hydrochlorothiazide

Brand: ATACAND HCT · — Part D claims (CY24) · First FDA approval: 2012-12-04

5 generic mfrs 0 plans require PA

Low NADAC$0.820

→

Avg plan cost$0.971

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

10

Captopril and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2023-02-14

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

11

Enalapril and Hydrochlorothiazide

Brand: Vaseretic · — Part D claims (CY24) · First FDA approval: 1986-10-31

2 generic mfrs 0 plans require PA

Low NADAC$0.170

→

Avg plan cost$0.189

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

12

Fosinopril and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2009-07-09

3 generic mfrs 0 plans require PA

Low NADAC$0.560

→

Avg plan cost$0.597

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

13

Lisinopril and Hctz

— Part D claims (CY24) · First FDA approval: 2025-12-03

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

14

Lisinopril and Hydrochlorothiazide

Brand: Zestoretic · — Part D claims (CY24) · First FDA approval: 2002-07-01

8 generic mfrs 0 plans require PA

Low NADAC$0.029

→

Avg plan cost$0.035

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

15

Lisinopril and Hydrochlorothiazide Tablets

Brand: Lisinopril and Hydrochlorothiazide · — Part D claims (CY24) · First FDA approval: 2015-03-12

Brand-only (no generics)

Low NADAC$0.029

→

Avg plan cost$0.035

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

16

Losartan and Hydrochlorothiazide

Brand: HYZAAR · — Part D claims (CY24) · First FDA approval: 2010-04-06

10 generic mfrs 0 plans require PA

Low NADAC$0.055

→

Avg plan cost$0.568

Part D spend — 10× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

17

Metoprolol and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2004-08-20

3 generic mfrs 0 plans require PA

Low NADAC$0.909

→

Avg plan cost$1.13

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

18

Olmesartan Medoxomil / Amlodipine Besylate / Hydrochlorothiazide

Brand: Tribenzor · — Part D claims (CY24) · First FDA approval: 2016-10-26

Brand-only (no generics) 0 plans require PA

Low NADAC$0.776

→

Avg plan cost$2.66

Part D spend — 3× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

19

Olmesartan Medoxomil Amlodipine and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2025-07-18

Brand-only (no generics)

Low NADAC$0.776

→

Avg plan cost$0.986

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

20

Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2025-05-15

7 generic mfrs

Low NADAC$0.776

→

Avg plan cost$0.986

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

21

Olmesartan Medoxomil and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2017-04-24

10 generic mfrs 0 plans require PA

Low NADAC$0.165

→

Avg plan cost$0.199

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

22

Olmesartan Medoxomil-Hydrochlorothiazide

Brand: Benicar HCT · — Part D claims (CY24) · First FDA approval: 2022-09-01

Brand-only (no generics) 0 plans require PA

Low NADAC$11.32

→

Avg plan cost$15.34

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

23

Quinapril and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 2004-03-31

2 generic mfrs 0 plans require PA Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

24

Quinapril and Hydrochlorothiazide 10/12.5

— Part D claims (CY24) · First FDA approval: 2016-07-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

25

Quinapril and Hydrochlorothiazide 20/12.5

— Part D claims (CY24) · First FDA approval: 2016-07-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

26

Quinapril and Hydrochlorothiazide 20/25

— Part D claims (CY24) · First FDA approval: 2016-07-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

27

Spironolactone and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 1979-08-03

2 generic mfrs 0 plans require PA

Low NADAC$0.483

→

Avg plan cost$0.483

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

28

Telmisartan and Hydrochlorothiazide

Brand: Micardis HCT · — Part D claims (CY24) · First FDA approval: 2000-12-01

6 generic mfrs 0 plans require PA

Low NADAC$0.314

→

Avg plan cost$1.16

Part D spend — 4× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

29

Triamterene and Hydrochlorothiazide

— Part D claims (CY24) · First FDA approval: 1993-09-23

8 generic mfrs 0 plans require PA

Low NADAC$0.097

→

Avg plan cost$0.115

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

30

Valsartan and Hydrochlorothiazide

Brand: Diovan HCT · — Part D claims (CY24) · First FDA approval: 1998-03-06

7 generic mfrs 0 plans require PA

Low NADAC$0.097

→

Avg plan cost$0.671

Part D spend — 7× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →